早期乳腺癌淋巴结手术与CDK4/6抑制剂:五项随机试验汇总分析
结果显示,为预防一例事件,SLNB联合瑞波西利需NNDT 123(iDFS)、129(DDFS)、345(OS);cALND联合阿贝西利需106(iDFS)、119(DDFS)、807(OS)。
要点
- 省略SLNB或cALND会限制分期信息,影响CDK4/6抑制剂资格判定。
- 为确定CDK4/6抑制剂资格而行腋窝手术的NNDT很高,总体生存获益边际。
- 仅以资格判定为目的的腋窝手术增加并发症和成本,临床应权衡。
核心结论
- 仅为了确定CDK4/6抑制剂资格而行SLNB或cALND需要极高的需诊断治疗人数,增加显著并发症和成本,总体生存获益仅边际。
主要发现
- SLNB联合瑞波西利:预防一例事件的NNDT为iDFS 123、DDFS 129、OS 345。
- cALND联合阿贝西利:预防一例事件的NNDT为iDFS 106、DDFS 119、OS 807。
关键数值与推荐
- SLNB联合瑞波西利预防一例iDFS事件的NNDT为123,DDFS为129,OS为345。
- cALND联合阿贝西利预防一例iDFS事件的NNDT为106,DDFS为119,OS为807。
临床怎么用
- 临床不应仅为判定CDK4/6抑制剂资格而常规行SLNB或cALND,应综合评估手术获益与风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Omitting sentinel lymph node biopsy (SLNB) and completion axillary lymph node dissection (cALND) in early-stage breast cancer reduces morbidity without compromising overall survival or recurrence rates. However, reduced axillary surgery restricts staging information, impacting eligibility for CDK4/6 inhibitors. We evaluated the impact of omitting SLNB or cALND on CDK4/6 inhibitor eligibility and the associated benefits and harms. METHODS: We used data from the SOUND, INSEMA, SENOMAC, monarchE, and NATALEE randomised trials. These five trials evaluated the safety of de-escalated lymph node surgery and adjuvant CDK4/6 inhibitors in patients with early breast cancer. The primary outcome was the number needed to diagnose and treat with CDK4/6 inhibitor-ie, number of axillary surgeries leading to adjuvant CDK4/6 inhibitor use, preventing one invasive disease-free survival event, distant disease-free survival event, or overall survival event at 5 years. FINDINGS: Between Jan 31, 2015, and Dec 31, 2021, 19 541 patients were randomly assigned and analysed within five trials, of whom 19 475 (99·7%) were women and 66 (0·3%) were men; median follow-up was 57·2 months (IQR 44·1-81·6). For SLNB and ribociclib, the number needed to diagnose and treat for one prevented event was 123 for invasive disease-free survival, 129 for distant disease-free survival, and 345 for overall survival. For cALND and abemaciclib, the number needed to diagnose and treat for one prevented event was 106 invasive disease-free survival, 119 for distant disease-free survival, and 807 for overall survival. INTERPRETATION: Performing SLNB or cALND solely to determine eligibility for CDK4/6 inhibition requires very high number needed to diagnose and treat, adds substantial morbidity, and is costly, with only marginal overall survival benefit. FUNDING: None.
引用
- Pfob A, Pham TH, de Boniface J, et al. Lymph node surgery and CDK4/6 inhibitors in early breast cancer: a pooled analysis from five randomised trials. Lancet Oncol. 2026. PMID: 42061372. doi:10.1016/S1470-2045(26)00064-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。